The healthcare provider wants to start empiric therapy on a client with signs and symptoms of infection. Which statement correctly describes empiric therapy?

Introduction: Empiric therapy involves the initiation of antimicrobial treatment based on a clinical conjecture of the most likely pathogens. This approach is utilized when the severity of the infection necessitates immediate intervention before definitive microbiological identification and susceptibility profiles can be established through laboratory culture techniques. A. Using a narrow-spectrum antibiotic for empiric therapy is generally avoided unless the pathogen is highly predictable. Narrow-spectrum agents target a limited range of bacteria; if the infecting organism falls outside that range, the therapy will fail, potentially leading to clinical deterioration of the patient while awaiting laboratory confirmation. B. Empiric therapy utilizes BROAD SPECTRUM antibiotics to provide immediate coverage against a wide variety of potential Gram-positive and Gram-negative pathogens. This "best guess" approach ensures that treatment begins while CULTURES AND SENSITIVITIES are pending, effectively reducing morbidity and mortality in patients with acute, undiagnosed infectious processes. C. While carbapenems are broad-spectrum, they are typically reserved as "last-line" agents for multidrug-resistant organisms. Using them routinely for initial empiric therapy in all cases violates ANTIMICROBIAL STEWARDSHIP principles. Empiric choice should be guided by local antibiograms and the specific site of infection rather than using a one-size-fits-all carbapenem. D. Restricting empiric therapy to only Gram-negative coverage is medically unsound unless the clinical presentation specifically points to such organisms. Most community and hospital-acquired infections can be caused by a mix of Gram-positive and Gram-negative bacteria; therefore, an effective empiric regimen must provide comprehensive, diversified antimicrobial activity.